Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE et al..  2017.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.. PLoS Med. 14(11):e1002417.

Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, Carrillo M, Martin H, Kasparian S, Syed P et al..  2017.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.. J Clin Invest. 127(1):260-268.

Feelixge HSDe Silva, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, Aubert M, Jerome KR.  2016.  Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.. Antiviral Res. 126:90-8.

Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A et al..  2016.  Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.. Science. 352(6288):1001-4.

Roychoudhury P, Feelixge HSDe Silva, Pietz HL, Stone D, Jerome KR, Schiffer JT.  2016.  Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases.. J Antimicrob Chemother. 71(8):2089-99.

Hile SJ, Feldman MB, Alexy ER, Irvine MK.  2016.  Recent Tobacco Smoking is Associated with Poor HIV Medical Outcomes Among HIV-Infected Individuals in New York.. AIDS Behav. 20(8):1722-9.

Halper-Stromberg A, Nussenzweig MC.  2016.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.. J Clin Invest. 126(2):415-23.

Kim SG, Lowe EL, Dixit D, Youn CSeyeon, Kim IJ, Jung JB, Rovner R, Zack JA, Vatakis DN.  2015.  Cocaine-mediated impact on HIV infection in humanized BLT mice.. Sci Rep. 5:10010.

Feldman MB, Thomas JA, Alexy ER, Irvine MK.  2015.  Crystal methamphetamine use and HIV medical outcomes among HIV-infected men who have sex with men accessing support services in New York.. Drug Alcohol Depend. 147:266-71.

Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, Wai B, Marmarelis E, Hernandez NJ, Yang OO, Currier JS et al..  2014.  HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.. Antivir Ther. 19(8):805-811.

Baker LM, Paul RH, Heaps JM, Westerhaus E, Chang JYoon, Williams S, Brier MR, Plax K, Ances BM.  2014.  Impact of human immunodeficiency virus on neurocognition and risky behaviors in young adults.. J Neurovirol. 20(5):466-73.

Kim SG, Jung JB, Dixit D, Rovner R, Zack JA, Baldwin GC, Vatakis DN.  2013.  Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection.. J Leukoc Biol. 94(4):835-43.

Zack JA, Kim SG, Vatakis DN.  2013.  HIV restriction in quiescent CD4⁺ T cells.. Retrovirology. 10:37.

Nixon CC, Vatakis DN, Reichelderfer SN, Dixit D, Kim SG, Uittenbogaart CH, Zack JA.  2013.  HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice.. Blood. 122(13):2195-204.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.  2012.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.. PLoS Pathog. 8(4):e1002649.

Zhang L, Lewin SR, Markowitz M, Lin HH, Skulsky E, Karanicolas R, He Y, Jin X, Tuttleton S, Vesanen M et al..  1999.  Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.. J Exp Med. 190(5):725-32.

Zhang L, Huang Y, Yuan H, Tuttleton S, Ho DD.  1997.  Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection.. Virology. 228(2):340-9.